Peptides for Cognitive Function & Brain Health: Evidence Review 2026

Semax is a heptapeptide fragment of ACTH(4-10) — literally the 4th through 10th amino acids of adrenocorticotropic hormone. It was developed in the 1980s by Russian neuropeptide researchers specifically as a nootropic agent. Proposed mechanism: Semax is claimed to increase BDNF (brain-derived neurotrophic factor) expression, particularly in the prefrontal cortex and hippocampus. BDNF is essential for synaptic plasticity, learning, and neuroprotection. Additionally, Semax is claimed to enhance dopamine and serotonin signaling and to have anti-inflammatory effects in the brain. Russian evidence: Russian studies on Semax are numerous and largely positive. A representative study (published in a Russian journal, translated to English) in patients with mild cognitive impairment found that Semax (intranasal, 1.5mg daily for 1 month) improved performance on cognitive testing, increased BDNF levels measured in blood plasma, and showed safety in EEG monitoring. Studies in healthy volunteers show Semax enhances memory consolidation in verbal and spatial learning tasks compared to placebo. Additionally, Semax is officially approved and registered in Russia by the Ministry of Health as a nootropic and cognitive enhancer. This regulatory approval is not equivalent to FDA approval and does not reflect the same evidence standards, but it does represent official recognition of presumed clinical benefit in Russia. Western evidence: Western replication of Semax studies is minimal. A search of PubMed for Semax conducted by Western research groups yields only a handful of results, most of which are theoretical or mechanistic (cell culture, rodent models) rather than human clinical trials. Several Western researchers have expressed skepticism about the effect sizes reported in Russian trials, citing methodological concerns. One Western study (published in 2016 in a neuropsychology journal) examined Semax in healthy adults using a randomized, placebo-controlled design with intranasal administration. Results showed modest improvements in some cognitive domains (attention, processing speed) but not others (memory, executive function). The effect sizes were smaller than those reported in Russian studies. Notably, researchers reported "a mild rhinitis or nasal discomfort" in some participants, raising questions about adequate blinding. The interpretation challenge: Is Semax genuinely more effective in Russian populations or study conditions? Are the higher effect sizes in Russian studies due to methodological differences (shorter outcome periods, questionnaire-based rather than objective cognitive testing, expectancy effects)? Or do Western trials with more rigorous blinding and objective endpoints simply reveal smaller true effects? The honest answer is unclear. The peptide has a plausible mechanism, Russian government approval, and positive Russian research data. However, independent Western replication suggests smaller effects than initially reported, and comprehensive Western clinical trials are lacking.

Selank is a heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from tuftsin, an immunomodulatory peptide. Like Semax, Selank was developed in Russia and is officially approved there as an anxiolytic and nootropic agent. Mechanism and Russian studies: Selank is claimed to enhance GABAergic signaling (the brain's primary inhibitory neurotransmitter system), increase serotonin, and modulate immune function through TLR4 activation. Russian studies report that Selank reduces anxiety (measured via standardized anxiety rating scales), enhances cognitive performance, and has immunomodulatory effects. A frequently cited trial involved patients with generalized anxiety disorder treated with intranasal Selank for 2-4 weeks, showing significant anxiety reduction compared to placebo. Additionally, like Semax, Selank is government-approved in Russia, suggesting official recognition of clinical utility. Western evidence gaps: Western research on Selank in humans is extremely limited. A PubMed search reveals primarily Russian-language publications and a few English-language papers describing the mechanism or animal studies. One small Western study in healthy volunteers (n=22, published 2012) examined Selank's effects on anxiety-related tasks during stress. Results showed some benefit in reducing stress-induced anxiety on certain measures, but effect sizes were modest and some secondary outcomes showed no difference from placebo. The GABA comparison: Selank is positioned as an anxiolytic, and its proposed mechanism (GABAergic enhancement) is plausible. However, for anxiety disorders, Western pharmacology has extensive RCT evidence for SSRIs, SNRIs, and benzodiazepines. Selank's effect sizes (based on available Western data) appear smaller than these established treatments. This doesn't mean Selank is ineffective, but it does mean it should be positioned as an exploratory option, not a replacement for evidence-based anxiety treatment. A key limitation: Many Selank studies measure anxiety via subjective scales (self-reported worry, visual analog scales) rather than objective neuroimaging or physiological markers. Placebo effects on anxiety are powerful; subjective improvement could reflect expectancy as much as pharmacological mechanism.

Dihexa (N-terminal tripeptide of human insulin-like growth factor I conjugated to a diketopiperazine) is a synthetic peptide designed to mimic hepatocyte growth factor (HGF). HGF is a potent mitogenic and neuroprotective growth factor implicated in synaptic plasticity and memory formation. The mechanism: In cell culture, Dihexa activates c-Met (the HGF receptor) on neurons, promoting neurite outgrowth, increasing synaptic density, and enhancing BDNF signaling. In rodent models, Dihexa improves memory consolidation and reverses cognitive decline in aging mice. A particularly compelling study (published in PNAS 2012) showed that Dihexa restored memory performance in aged rats to levels observed in young controls — a dramatic effect by animal model standards. Human evidence: There are essentially no published human clinical trials of Dihexa in humans. A handful of case reports and open-label observations from functional medicine practitioners describe subjective cognitive improvement, but these lack control groups and objective outcome measures. The drug has not advanced to formal clinical trials in the United States. Why the enthusiasm despite absent human data? Dihexa's mechanism is mechanistically elegant (mimicking a well-understood growth factor), and animal evidence is genuinely impressive. However, translating rodent cognitive improvement to human clinical benefit is notoriously difficult — many compounds that improve memory in rats fail to show clinical benefit in humans. Current development status: As of 2026, Dihexa has not been licensed for human use and is not available through regulated pharmaceutical channels. Interest in the compound has waxed and waned in the research community. The absence of human trials represents a significant limitation.

NAD+ (nicotinamide adenine dinucleotide) is a fundamental cofactor in mitochondrial energy production and cellular signaling. NAD+ levels decline with age, and this decline is associated with cognitive aging. Several peptide-based approaches aim to boost NAD+: some directly carry NAD+ (which faces absorption challenges), others are peptides fused to NAD+ precursor molecules like NMN or NR. The NAD+ evidence base: NMN and NR (non-peptide forms) have human RCT evidence for metabolic and mitochondrial benefits. Studies show that NMN/NR supplementation increases muscle NAD+ levels, improves insulin sensitivity, and in some studies, enhances physical performance. However, human cognitive outcomes have not been extensively studied. A few small studies in aging humans found that NMN supplementation improved subjective cognitive function (fatigue, mental clarity), but did not use objective cognitive testing. Peptide-fusion approaches: Several biotech companies have developed peptide carriers for NAD+ or NAD+ precursors, designed to improve brain penetration and cellular uptake. These are largely preclinical. One such compound (a peptide-NMN conjugate) showed improved brain NAD+ levels in mouse models, but human trials are lacking. The mitochondrial reasoning: The mechanistic argument is solid — brain aging correlates with mitochondrial decline, NAD+ restoration could theoretically support cognitive aging prevention. However, most published human evidence for NAD+ enhancement comes from non-peptide forms (standalone NMN/NR), and even for these, cognitive endpoints are sparsely studied. Peptide-fused versions remain experimental.

BPC-157 returns again in this context. The mechanism for neuroprotection is similar to its gut and tissue healing properties: angiogenesis, growth factor signaling, and anti-inflammation. Brain-specific studies show:

• Stroke protection: In rats with induced ischemic stroke, BPC-157 reduces infarct volume and improves neurological recovery. Effect sizes are modest but consistent across studies.
• Neurotoxin protection: In models of Parkinson's disease and other neurodegenerative conditions, BPC-157 provides neuroprotection in rodent models.
• Neuroinflammation: In neuroinflammatory models, BPC-157 reduces glial activation and pro-inflammatory cytokine production.

The human evidence gap: There are zero published human clinical trials of BPC-157 for cognitive enhancement or neuroprotection. The mechanistic plausibility and animal evidence are genuine, but claims that BPC-157 is a cognitive enhancer are extrapolations from animal studies, not established human fact. The BBB problem: A critical issue is blood-brain barrier (BBB) penetration. Most peptides do not cross the BBB efficiently. BPC-157 may cross the BBB slightly more than some peptides, but this is not well-characterized. Systemic administration of BPC-157 may provide indirect neuroprotection through anti-inflammatory effects on peripheral immune cells (which do cross the BBB), but direct brain tissue levels of intact peptide are unknown.

GHK-Cu (glycine-histidine-lysine copper peptide) is the same copper tripeptide widely marketed for skin collagen production. However, GHK-Cu also has broader effects on gene expression that could theoretically support brain health. Gene expression effects: In cell culture, GHK-Cu modulates expression of genes involved in collagen synthesis, angiogenesis, and tissue remodeling. At a more fundamental level, GHK activates multiple signaling pathways including TGF-β, MAP kinases, and growth factor receptors. In neurons specifically, GHK-Cu promotes neurite outgrowth in vitro and enhances neuronal survival under stress conditions. Systemic effects: Some studies suggest GHK-Cu reduces systemic inflammation and enhances immune regulation. Chronic systemic inflammation is associated with cognitive aging; reducing it could theoretically support brain health indirectly. Human cognitive evidence: There are no published human RCTs examining GHK-Cu's effects on cognitive function. The neuronal culture studies are suggestive but preliminary. GHK-Cu is marketed primarily as a skin and wound-healing peptide; cognitive claims are extrapolations from basic science.

A legitimate scientific question is why effect sizes in Russian neuropeptide studies tend to be larger than Western replication attempts. Several explanations are possible:

• Methodological differences: Russian studies may use shorter intervention periods, simpler outcome measures, or different statistical approaches that detect effects more easily. Western trials often use longer follow-up periods and more stringent outcome definitions.
• Publication bias: Negative studies may be published less frequently in Russian journals with lower international visibility. Western investigators may be more likely to submit null results to major journals.
• Regulatory tradition: Soviet-era medical research developed different standards for evidence compared to Western FDA/EMA frameworks. This reflects different regulatory philosophies, not necessarily inferior research, but creates different evidentiary standards.
• Population differences: Peptides might work better in Russian populations due to genetic, dietary, or environmental factors. This is speculative but not impossible.
• Expectancy effects: In countries where a peptide is government-approved and well-known, placebo effects might be stronger. Blinding integrity may be harder to maintain.
• True effect differences: Russian researchers may simply have better understanding of optimal dosing, administration route, or patient selection that maximizes efficacy. This is possible but would require Western researchers to adequately replicate these conditions.

The most likely explanation is a combination of these factors. The implication is that Western evaluation of Russian-developed peptides requires independent RCTs under Western methodological standards — and effect sizes from Western trials should be given greater weight than historical Russian data.

Tier 1 (Solid mechanism, extensive animal data, modest Western human data): Semax — Multiple mechanisms (BDNF, monoamine signaling), Russian government approval, positive animal and Russian human trials, some Western replication showing modest effects. More evidence than other nootropic peptides, but Western effect sizes smaller than Russian claims. Tier 2 (Plausible mechanism, limited Western human data): Selank — GABA-enhancing mechanism is well-understood, Russian approval, animal evidence, one small Western study showing modest anxiety reduction. Insufficient data for strong recommendation. Tier 3 (Elegant mechanism, impressive animal data, zero human RCTs): Dihexa — HGF mimetic with stunning rodent memory data; plausible human applicability but entirely unproven in humans. High mechanistic promise, zero clinical evidence. Research-stage compound. Tier 4 (Indirect mechanism, limited human evidence for cognitive benefits): NAD+ peptide conjugates — Mitochondrial logic is sound, but most evidence comes from non-peptide NAD+ precursors, and human cognitive outcomes are sparsely studied. Preliminary but not well-established. Tier 5 (Mechanistically plausible, animal evidence only): BPC-157 for cognition — Reasonable neuroprotection mechanism and rodent stroke data; zero human cognitive trials. Do not market as nootropic without human evidence. Tier 6 (Supportive but not primary for cognition): GHK-Cu — Positive effects on gene expression and neuronal culture; no human cognitive trials. Can be considered as part of general health optimization, not as targeted cognitive enhancer.

If the goal is evidence-based cognitive enhancement, the comparison hierarchy should be:

• Level 1 (Proven, highest evidence): Cognitive training (working memory training, spaced learning), physical exercise, sleep quality, Mediterranean diet pattern. Extensive RCT evidence, large effect sizes for age-related cognitive decline prevention.
• Level 2 (Some human RCT evidence): Caffeine for acute cognitive performance, L-theanine for focus, fish oil (omega-3) for memory in some populations. Modest but reliable effect sizes.
• Level 3 (Mechanistically plausible, limited human trials): Semax, NAD+ precursors, piracetam. Some human data, but effect sizes modest and Western replication limited.
• Level 4 (Promising mechanisms, minimal human evidence): Selank, GHK-Cu. Require Western clinical trials.
• Level 5 (Exciting preclinical data, zero human proof): Dihexa, BPC-157 for cognition. Do not recommend without human trials.

Cognitive aging is too important to skip fundamental interventions (exercise, sleep, diet, cognitive training) in favor of untested peptides. Peptides might represent an adjunctive option once basics are optimized and assessed through functional neuroimaging or cognitive testing.